|
Mar 28
|
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
|
|
Mar 26
|
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
|
|
Mar 25
|
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
|
|
Mar 20
|
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 11
|
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
|